| Literature DB >> 24581461 |
Riccardo Lencioni1, Camillo Aliberti2, Thierry de Baere3, Ricardo Garcia-Monaco4, Govindarajan Narayanan5, Elizabeth O'Grady6, William S Rilling7, Duncan Walker8, Robert C G Martin9.
Abstract
Transcatheter hepatic arterial administration of irinotecan-loaded drug-eluting beads (DEBIRI) is used to treat liver-only or liver-dominant metastatic disease from colorectal cancer (CRC). Eligibility for DEBIRI should be established in each individual patient by a multidisciplinary team based on comprehensive clinical, imaging, and laboratory assessment. Standardization of DEBIRI technique and protocols would be expected to lead to improved efficacy and safety. The present article provides a set of technical recommendations for the use of DEBIRI in the treatment of hepatic CRC metastases.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24581461 DOI： 10.1016/j.jvir.2013.11.027
Source DB: PubMed Journal: J Vasc Interv Radiol ISSN： 1051-0443 Impact factor: 3.464